证券代码：300558 证券简称：贝达药业 公告编号：2025-084 一、被提名人已经通过贝达药业股份有限公司第四届董事会提名委员会或 者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可 能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券 交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 贝达药业股份有限公司 独立董事提名人声明与承诺 提名人贝达药业股份有限公司董事会现就提名叶建亮为贝达药业股份有限 公司第五届董事会独立董事候选人发表公开声明。被提名人已书面同意作为贝 达药业股份有限公司第五届董事会独立董事候选人(参见该独立董事候选人声 明)。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全 部兼职、有无重大失信等不良记录等情况后作出的，本 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-088 贝达药业股份有限公司 独立董事候选人声明与承诺 声明人叶建亮作为贝达药业股份有限公司（以下简称"公司"）第五届董事 会独立董事候选人，已充分了解并同意由提名人公司董事会提名为公司第五届董 事会独立董事候选人。现公开声明和保证，本人与公司之间不存在任何影响本人 独立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如 下事项： 1、本人已经通过公司董事会提名委员会资格审查，提名人与本人不存在利害关系 或者其他可能影响独立履职情形的密切关系。 √是 □否 如否，请详细说明：____________________ 2、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任公司董 事的情形。 √是 □否 如否，请详细说明：____________________ 3、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务规 则规定的独立董事任职资格和条件。 √是 □否 如否，请详细说明：____________________ 4、本人符合 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-091 贝达药业股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）第四届董事会第二十九次会议 决定于 2025 年 12 月 31 日（星期三）15:00 召开 2025 年第二次临时股东大会（以 下简称"本次股东大会"），现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：公司第四届董事会第二十九次会议审议通过《关 于提请召开 2025 年第二次临时股东大会的议案》，本次会议的召集、召开符合《中 华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、 部门规章、规范性文件及《贝达药业股份有限公司章程》的有关规定。 4、会议召开日期和时间 现场会议召开日期、时间：2025 年 12 月 31 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-077 贝达药业股份有限公司 第四届监事会第二十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席张洋南先生召集，会议通知于 2025 年 12 月 8 日 以电子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2025 年 12 月 15 日在公司杭州总部 3 楼会议室召开，采取 现场会议和电话会议相结合的方式，现场投票表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席张洋南先生主持，公司证券事务代表沈剑豪先 生列席了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《贝达药业股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 二、监事会会议审议情况 1、会议审议并通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》 经认真审核 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-076 贝达药业股份有限公司 第四届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长丁列明先生召集，会议通知于 2025 年 12 月 8 日以电 话、邮件等形式送达全体董事，董事会会议通知中包括会议的相关材料，同时列 明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 12 月 15 日在公司杭州总部行政大楼十五楼会议室 召开，采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 12 人，实际出席会议人数 12 人。 4、本次董事会由董事长丁列明先生主持，公司董事会秘书吴灵犀先生列席 了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《贝达药业股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 二、董事会会议审议情况 1、会议审议并通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》 根据《深圳证券交易所 ...

Core Viewpoint - Beida Pharmaceutical Co., Ltd. announced that four of its innovative drugs have been included in the National Medical Insurance Directory for 2025, reflecting the recognition of the company's innovation capabilities and the clinical value of its drugs by the national medical insurance department [1][5]. Group 1: Drug Information - The four drugs included are: 1. **Erlotinib Hydrochloride Tablets** - the first domestically developed EGFR-TKI for lung cancer treatment with independent intellectual property rights [1]. 2. **Ensartinib Capsules** - a new generation ALK inhibitor co-developed with Xcovery [1]. 3. **Befotnib** - a third-generation EGFR-TKI and a national class 1 innovative drug with independent intellectual property rights [2]. 4. **Vorolanib Tablets** - a new multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and is used for treating pathological angiogenesis diseases [2]. Group 2: Impact on Business - Inclusion in the National Medical Insurance Directory is expected to enhance the accessibility of these products and positively impact sales [5]. - The directory will be effective from January 1, 2026, and the immediate impact on the company's operating performance cannot be accurately estimated at this time [5].

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Core Viewpoint - The announcement by Beida Pharmaceutical regarding the inclusion of its products in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 is a significant development for the company and its market positioning [1] Group 1 - Beida Pharmaceutical has announced that its products, including Alectinib Hydrochloride Tablets, Ensartinib Capsules, Bafetinib Mesylate Capsules, and Vorinostat Tablets, have been included in the National Drug List for 2025 [1]

Core Viewpoint - Betta Pharmaceuticals has announced that several of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance the accessibility and market potential of these drugs [1] Group 1 - Betta Pharmaceuticals' products included in the 2025 drug list are: - Hydrochloride Alectinib Tablets (Kaimena) - Hydrochloride Ensartinib Capsules (Beimana) - Mesylate Bafetinib Capsules (Saimena) - Voronib Tablets (Fumeina) [1] - Additionally, the company's Bevacizumab Injection (Beanding) has been included in the National Medical Insurance Category B drug list [1]

Core Viewpoint - The announcement indicates that several products from the company have been included in the National Medical Insurance Drug List for 2025, which is expected to enhance accessibility and positively impact sales, although the exact effect on current performance cannot be accurately estimated [1] Group 1 - The products included are: - Hydrochloride Alectinib Tablets - Hydrochloride Ensartinib Capsules - Mesylate Bafetinib Capsules - Vorinostat Tablets These products will be effective from January 1, 2026, to December 31, 2027 [1] - Additionally, the product Bevacizumab Injection has been included in the National Medical Insurance Category B Drug List [1] Group 2 - Inclusion in the medical insurance list is expected to improve product accessibility [1] - The impact on sales is anticipated to be positive, although the company cannot currently provide an accurate estimate of the effect on its performance [1]